X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Medicare Monday: A closer look at Medicare Part B

By Kelsey Lang  |    January 16, 2017
We took a deeper dive on Medicare Part D last week, so today we’re switching gears and talking about Medicare Part B.   Read More

The 20-year journey yielding a new weapon against cancer

By Andrew Powaleny  |    January 10, 2017
Developing new medicines is a long, complex process. On average, it takes at least 10-12 years for a new medicine to complete the journey from initial discovery to becoming part of a patient’s...   Read More

Significant progress fighting cancer: Death rate has dropped 25 percent

By Holly Campbell  |    January 9, 2017
Cancers have long been one of the most devastating and complex disease areas facing patients. But thanks in part to innovative advancements in treatments and early detection, the cancer death rate...   Read More

Medicare Monday: A refresh on private negotiation in Part D

By Nicole Longo  |    January 9, 2017
Last week, we highlighted a number of Medicare resources – from how to learn more about which medicines are covered in Part B to how Part D has been a success since its implementation. And this...   Read More

3 things to know about 2016 drug approvals

By Andrew Powaleny  |    January 6, 2017
In 2016, the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) approved 22 new medicines to treat a broad range of illnesses for patients in need. These...   Read More

Medicare Monday: Kicking off 2017 with Medicare resources

By Nicole Longo  |    January 2, 2017
Happy New Year, #MedicareMonday readers!   Read More

Medicare Monday: Looking back at the success of Part D in its first 10 years

By Nicole Longo  |    December 26, 2016
As 2016 comes to a close this week, Medicare Part D wraps up its first decade – and it’s been quite a busy decade. Today, more than 40 million people, including seniors and people living with...   Read More

Medicare Monday: New research finds trends in Average Sales Price of Part B drugs remains stable

By Kelsey Lang  |    December 19, 2016
Earlier this year, we looked at Average Sales Price (ASP) and how it works in Medicare Part B. As you may remember, ASP (the method for reimbursing drugs covered by Part B) is a market-based price...   Read More

New report provides recommendations for securing and protecting IP

By Mark Grayson  |    December 13, 2016
This week, the White House Office of the U.S. Intellectual Property Enforcement Coordinator (IPEC) issued a Joint Strategic Plan outlining actions government, industry, educational institutions...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates